Cancer Drug Parity Act of 2026

Lower out-of-pocket for oral cancer drugs

This bill would require group health plans and insurance sold with those plans to make cost-sharing for FDA‑approved, patient‑administered anticancer drugs no less favorable than cost-sharing for the same drugs given by IV or injection. The rule would apply only when a treating physician finds the oral drug medically necessary to kill, slow, or prevent cancer cells, or clinically appropriate in type, frequency, extent, site, and duration. Cost-sharing means deductibles, coinsurance, copayments, and any limits on applying those charges. Plans could not redesign or reclassify benefits to raise out-of-pocket costs, but they could still use prior authorization and other utilization controls. The requirement would apply to plan years beginning on or after January 1, 2027, and state laws that give stronger protections would still apply.